TLC BioSciences (7924) Stock Overview

Operates as a clinical-stage biotechnology company that develops and sells lipid-engineered medicines in Taiwan, the United States of America, Europe, and the Cayman Islands. More details

7924 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Shares are highly illiquid

7924 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

TLC BioSciences Corp. Competitors

Price History & Performance

Summary of share price highs, lows and changes for TLC BioSciences
Historical stock prices
Current Share Price	NT$210.50
52 Week High	NT$300.00
52 Week Low	NT$202.00
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent updates

Shareholder Returns

	7924	TW Biotechs	TW Market
7D	n/a	4.3%	-4.3%
1Y	n/a	53.5%	95.6%

Return vs Industry: Insufficient data to determine how 7924 performed against the TW Biotechs industry.

Return vs Market: Insufficient data to determine how 7924 performed against the TW Market.

Price Volatility

Is 7924's price volatile compared to industry and market?
7924 volatility
7924 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.0%
Market Average Movement	6.5%
10% most volatile stocks in TW Market	12.1%
10% least volatile stocks in TW Market	2.6%

Stable Share Price: 7924's share price has been volatile over the past 3 months compared to the TW market.

Volatility Over Time: Insufficient data to determine 7924's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1997	n/a	George Yeh	www.tlcbio.com/en

TLC BioSciences Corp. operates as a clinical-stage biotechnology company that develops and sells lipid-engineered medicines in Taiwan, the United States of America, Europe, and the Cayman Islands. It offers products based on its proprietary LipAD, a drug delivery platforms, including BioSeizer for sustained release; NanoX for targeted delivery; and Genosphere for regenerative medicine. The company's pipeline includes candidates for orthopedics and pain management, metabolic and immune disorders, and infectious diseases.

TLC BioSciences Corp. Fundamentals Summary

How do TLC BioSciences's earnings and revenue compare to its market cap?
7924 fundamental statistics
Market cap	NT$28.11b
Earnings (TTM)	NT$0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is 7924 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
7924 income statement (TTM)
Revenue	NT$0
Cost of Revenue	NT$0
Gross Profit	NT$0
Other Expenses	NT$0
Earnings	NT$0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did 7924 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/27 12:32
End of Day Share Price	2026/06/26 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

TLC BioSciences Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

TLC BioSciences Corp.TPEX:7924 Stock Report